NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Forecast, Price & News

$2.90

+0.16 (+5.84%)

(As of 01:50 PM ET)

Compare

Today's Range: $2.74
▼
$2.92
50-Day Range: $2.74
▼
$4.79
52-Week Range: $2.65
▼
$8.66

Volume: 397,035 shs
Average Volume: 100,396 shs
Market Capitalization: $158.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Prelude Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 227.6% Upside
$9.50 Price Target
Short Interest: Bearish
6.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.36) to ($2.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

646th out of 963 stocks

Pharmaceutical Preparations Industry

291st out of 451 stocks

3.0

Analyst's Opinion

Consensus Rating
Prelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Prelude Therapeutics has a forecasted upside of 227.6% from its current price of $2.90.
Amount of Analyst Coverage
Prelude Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.92% of the float of Prelude Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Prelude Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Prelude Therapeutics has recently increased by 1.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Prelude Therapeutics does not currently pay a dividend.
Dividend Growth
Prelude Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRLD.

3.3

News and Social Media Coverage

News Sentiment
Prelude Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for PRLD on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
79.54% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.34% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Prelude Therapeutics are expected to grow in the coming year, from ($2.36) to ($2.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prelude Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prelude Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prelude Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prelude Therapeutics (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

PRLD Price History

30 days | 90 days | 365 days | Advanced Chart

PRLD Stock News Headlines

August 29, 2023 | finance.yahoo.com

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

August 29, 2023 | finance.yahoo.com

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 17, 2023 | msn.com

HC Wainwright & Co. Reiterates Prelude Therapeutics (PRLD) Buy Recommendation

August 17, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Prelude Therapeutics (PRLD)

August 3, 2023 | finance.yahoo.com

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 10, 2023 | finance.yahoo.com

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

June 22, 2023 | marketwatch.com

8-K: Prelude Therapeutics Inc

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

June 22, 2023 | benzinga.com

Board Member at Prelude Therapeutics Acquires Company Stock Options Worth 47,000 Shares

June 4, 2023 | benzinga.com

Prelude Therapeutics Stock (NASDAQ:PRLD), Insider Trading Activity

June 2, 2023 | msn.com

The Prognosis For Prelude Therapeutics

May 31, 2023 | finance.yahoo.com

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 28, 2023 | finance.yahoo.com

Krishna Vaddi Buys Handful Of Shares In Prelude Therapeutics

May 28, 2023 | finance.yahoo.com

Krishna Vaddi Buys Handful Of Shares In Prelude Therapeutics \

May 25, 2023 | benzinga.com

5.00M Reasons To Be Bullish On Prelude Therapeutics Stock

May 18, 2023 | finanznachrichten.de

Prelude Therapeutics, Inc.: Prelude Therapeutics Announces Launch of Proposed Public Offering

May 18, 2023 | finance.yahoo.com

Prelude Therapeutics Announces Pricing of Public Offering

May 8, 2023 | finanznachrichten.de

Prelude Therapeutics, Inc.: Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023 | msn.com

Prelude Therapeutics GAAP EPS of -$0.58 beats by $0.10

May 8, 2023 | finance.yahoo.com

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

April 28, 2023 | marketwatch.com

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

April 27, 2023 | finance.yahoo.com

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

April 11, 2023 | finance.yahoo.com

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

April 7, 2023 | finance.yahoo.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) most popular amongst private equity firms who own 33% of the shares, institutions hold 24%

March 26, 2023 | finance.yahoo.com

The 7 Worst Stocks to Buy Now

March 17, 2023 | seekingalpha.com

Prelude Therapeutics GAAP EPS of $2.44

See More Headlines

Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Company Calendar

Last Earnings: 8/03/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRLD
CUSIP: N/A
CIK: 1678660
Web: www.preludetx.com
Phone: 302-467-1280
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.50
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +227.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-115,440,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.93%
Return on Assets: -49.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.13
Quick Ratio: 17.13

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.09 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 54,810,000
Free Float: 11,214,000
Market Cap: $158.95 million
Optionable: Not Optionable
Beta: 0.33

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Krishna Vaddi D.V.M. (Age 57)
Ph.D., Founder, CEO & Director
Comp: $805.91k

Dr. Edna Huang M.D. (Age 50)
Pres & Chief Medical Officer
Comp: $563.55k

Dr. Peggy A. Scherle Ph.D. (Age 62)
Chief Scientific Officer
Comp: $868.62k

Mr. Laurent Chardonnet M.B.A. (Age 58)
Chief Financial Officer

Ms. Aimee Crombie Ph.D.
Sr. VP and Head of Strategic Planning & Operations

Dr. Madhu Pudipeddi Ph.D.
Sr. VP of Technical Operations

Lindsey Trickett
VP of Investor Relations

Mr. Bryant David Lim J.D. (Age 52)
Chief Legal Officer & Corp. Sec.

Ms. Michele Porreca M.B.A.
Chief People Officer

Dr. Andrew P. Combs Ph.D. (Age 57)
Exec. VP & Head of Chemistry

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRLD Stock - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRLD, but not buy additional shares or sell existing shares.
View PRLD analyst ratings or view top-rated stocks.
What is Prelude Therapeutics' stock price forecast for 2023?: 4 equities research analysts have issued 12 month price objectives for Prelude Therapeutics' stock. Their PRLD share price forecasts range from $5.00 to $17.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 227.6% from the stock's current price.
View analysts price targets for PRLD or view top-rated stocks among Wall Street analysts.
How have PRLD shares performed in 2023?: Prelude Therapeutics' stock was trading at $6.04 on January 1st, 2023. Since then, PRLD stock has decreased by 52.0% and is now trading at $2.90.
View the best growth stocks for 2023 here.
When is Prelude Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PRLD earnings forecast.
How were Prelude Therapeutics' earnings last quarter?: Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.11.
When did Prelude Therapeutics IPO?: (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?: Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."
Who are Prelude Therapeutics' major shareholders?: Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (4.55%), BlackRock Inc. (1.57%), Woodline Partners LP (0.45%), Geode Capital Management LLC (0.44%), State Street Corp (0.34%) and Renaissance Technologies LLC (0.33%). Insiders that own company stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Jane Huang, Krishna Vaddi, Laurent Chardonnet, Orbimed Advisors Llc and Peggy Scherle.
View institutional ownership trends.
How do I buy shares of Prelude Therapeutics?: Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Prelude Therapeutics' stock price today?: One share of PRLD stock can currently be purchased for approximately $2.90.
How much money does Prelude Therapeutics make?: Prelude Therapeutics (NASDAQ:PRLD) has a market capitalization of $158.95 million. The company earns $-115,440,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.
How many employees does Prelude Therapeutics have?: The company employs 122 workers across the globe.
How can I contact Prelude Therapeutics?: The official website for the company is www.preludetx.com. The company can be reached via phone at 302-467-1280 or via email at prelude@argotpartners.com.

This page (NASDAQ:PRLD) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial